[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
FrillePelle @FrillePelle on x XXX followers
Created: 2024-06-24 09:41:31 UTC
CANTARGIA
Conclusions: Data from PDAC patients receiving nadunolimab + GN and experiments in preclinical models suggest that targeting IL1RAP by nadunolimab may combine antitumor activity with potent reduction of CIPN
$CANTA
XXX engagements
Related Topics $canta